| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424100610 | In an inorganic compound | 76 |
| 20080206134 | Radio-opaque hemostatic agents and devices and methods for the delivery thereof - A radiographic composition for promoting the formation of clots in blood includes a zeolite and iodine. A device for promoting the clotting of blood at an internal wound site includes a catheter; a delivery instrument insertable through the catheter; a radioopaque blood clotting agent that deliverable through the delivery instrument; and a positive pressure apparatus that can dispense the blood clotting agent to the wound site through the delivery instrument. A system for radiographically imaging an internally bleeding wound includes means for delivering a radioopaque blood clotting agent and means for radiographically imaging the radioopaque blood clotting agent. A method of imaging an internally bleeding wound includes the steps of inserting a catheter into a patient; advancing the catheter to a point adjacent the bleeding wound; depositing a radioopaque zeolite at the bleeding wound; and imaging the radioopaque zeolite to monitor blood-clotting caused by the zeolite. | 08-28-2008 |
| 20080213172 | RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES - Conjugates, methods and kits are described for imaging tissues and organs that express one or more peptidases. In a preferred embodiment of the invention, a series of di-(2-pyridylmethyl)amine (D) ligands, which can bind M(CO) | 09-04-2008 |
| 20080226549 | BREAST CANCER ERADICATION PROGRAM - A method of treating breast cancer that is at least partially ER | 09-18-2008 |
| 20080286200 | LYOPHILIZED EDIBLE FOOD INCORPORATING A MARKER AND METHODS OF MAKING - A standardized, lyophilized edible food containing a biologically safe stable marker for use in the measurement of gastric emptying by the quantification of marker excreted in the breath of the patient. | 11-20-2008 |
| 20090028787 | Novel Heteroaryl Substituted Benzothiazoles - The present invention relates to novel heteroaryl substituted benzothiazole derivatives, precursors thereof, and therapeutic uses for such compounds, having the structural formula (I) below: [Chemical formula should be inserted here. Please see paper copy] and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzothiazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. | 01-29-2009 |
| 20090117039 | CHARGED BIODEGRADABLE POLYMERS FOR MEDICAL APPLICATIONS - In accordance with one aspect of the invention, implantable medical devices are provided which include polymeric compositions that comprise at least one type of biodegradable ionic polymer. The at least one type of biodegradable ionic polymer comprises a biodegradable polymer core and one or more ionic end groups. | 05-07-2009 |
| 20090155167 | AUTOMATED METHOD - The present invention provides an automated method for the preparation of | 06-18-2009 |
| 20090191122 | METHOD FOR PURIFICATION OF 225AC FROM IRRADIATED 226RA-TARGETS - The present invention describes a method for purification of | 07-30-2009 |
| 20090202434 | Pharmaceutical Composition and Dressing for Treating Skin Lesion, as Well as the Use of Cerium Salt Associated With a Collagen Matrix - The present invention refers to a pharmaceutical composition for treating skin lesion, comprising a cerium salt on a collagen matrix and a dermatologically acceptable carrier. The present invention also refers to a wound dressing for treating skin lesion, comprising the pharmaceutical composition of the present invention. The present invention further refers to the use of a cerium salt associated with collagen in the preparation of the pharmaceutical composition or wound dressing according to the present invention. The composition of the present invention can be used in topical applications in a variety of lesion types, such as skin lesions involving the release of toxins related to microbial proteins on human or animal organisms, or those appointed as HSP; burns which involve burned skin toxin formation or LPC; chronically ulcerate skin lesions in which there is an overproduction of proteinase; skin lesions of difficult resolution, in which control of exudate overproduction is required; and critically infected or colonized skin lesions. | 08-13-2009 |
| 20090257949 | Radiopharmaceutical Imaging of Neurodegenerative Diseases - Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein. | 10-15-2009 |
| 20090263319 | METHODS AND COMPOSITIONS FOR TREATING POSTOPERATIVE PAIN COMPROSING KETOROLAC - Methods and compositions are provided for reducing, treating or preventing postoperative pain or inflammation in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of ketorolac or pharmaceutically acceptable salt thereof to a target tissue site, wherein the drug depot releases an effective amount of ketorolac or pharmaceutically acceptable salt thereof over a period of 3 to 10 days. | 10-22-2009 |
| 20090297441 | Imaging Agents - The use of silicon as an imaging agent is described. | 12-03-2009 |
| 20090297442 | RADIOPHARMACEUTICAL PRODUCTS - The present invention relates to improved radiopharmaceutical compositions in sealed containers, where the container closure has an ETFE (ethylene-tetrafluoroethylene copolymer) coating. Also disclosed are kits for radiopharmaceutical preparation using the sealed containers, as well as methods of preparation of radiopharmaceuticals using the sealed containers. | 12-03-2009 |
| 20090304582 | Imaging Protocols - Protocols for radioimaging an event or disorder are provided. An exemplary protocol comprises a method of radioimaging a myocardial perfusion, the method comprising in sequence:
| 12-10-2009 |
| 20090311175 | METHODS FOR TREATING THYROID CANCER - The invention provides methods for enhancing iodine absorption in a thyroid in a subject and treating thyroid cancer by administering to the subject a composition which includes a multi-kinase inhibitor. Furthermore, the invention provides methods for improving a medical diagnostic procedure based on radioactive iodine in a subject by administering to the subject a composition comprising a multi-kinase inhibitor. | 12-17-2009 |
| 20090317325 | Diagnostic Substance and Method for the Analysis of Metabolism Processes in the Brain - The present invention relates to a diagnostic substance, containing at least one complex of lipophilic anions and metal ions, wherein the lipophilic anions are selected from the group comprising: triethylene tetramine dihydrochloride (TETA), ethyl cysteinate dimer (ECD), methoxyisobutylisonitrile (MIBI), HMPAO (d,l-hexamethylpropylene aminoxime), ethylenediamine N,N,N′,N′-tetraacetanilide (EDTAN), dimethyldithiocarbamate (DMC) and diethyldithiocarbamate (DDC) and glycine N,N′-[1,2-ethanediylbis(oxy-2,1-phenylene)]bis [N-(carboxymethyl)-1,1′-bis[2-(octadecyloxy)ethyl]ester (DP-109), and wherein the metal ions are selected from the group comprising thallium isotopes, lead isotopes, cobalt isotopes and manganese isotopes, together with solvents, adjuvants and/or vehicles. The diagnostic substance is used for investigating metabolic processes in the brain and/or central nervous system (CNS). | 12-24-2009 |
| 20090324493 | METHOD FOR PREPARING A SALINE SOLUTION COMPRISING [13N] NH4 + AND USE OF A DEVICE - The invention relates to a method for preparing a saline solution comprising [13N]NH4+. The method comprises following steps: preparing [13N]NH3 gas, transporting [13N]NH3 gas to a diffusion chamber, to a first side of a semipermeable membrane, transporting sterile saline solution to the diffusion chamber, to a second side of a semipermeable membrane, allowing the mixing of [13N]NH3 gas that has penetrated the semipermeable membrane with the saline solution on the second side of the semipermeable membrane, whereby saline solution comprising [13N]NH4+ is obtained, and directing the saline solution comprising [13N]NH4+ out from the diffusion chamber. The invention relates also to use of a device for preparing a radiolabelled saline solution for preparation of a saline solution comprising [13N]NH4+. | 12-31-2009 |
| 20100008854 | METAL NANOCOMPOSITE, PREPARATION METHOD AND USE THEREOF - The disclosure provides metal nanocomposites including one or more metal nanoparticles having a hydrophobic surface and at least partially enclosed by cationic and hydrophilic polymers. The metal nanocomposites are useful as among others, a contrast agent, a diagnostic composition or a pharmaceutical composition. | 01-14-2010 |
| 20100111857 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
| 20100143247 | DIAGNOSIS OF PROSTATE CANCER - The present invention provides a method for determining the presence of prostate cancer in a subject which method comprises determining the level of expression of one or more markers in a blood sample from the subject, wherein said one or more markers comprise at least one of E2F3, c-met, pRB, EZH2, e-cad, CAXII, CAIX, HIF-1α, Jagged, PIM-1, hepsin, RECK, Clusterin, MMP9, MTSP-1, MMP24, MMP15, IGFBP-2, IGFBP-3, E2F4, caveolin, EF-1A, Kallikrein 2, Kallikrein 3 and PSGR. | 06-10-2010 |
| 20100150830 | METHOD OF TREATING CANCER - A method and composition for administering a therapeutic agent to a lesion comprising a contrast/carrier agent and ethanol. | 06-17-2010 |
| 20100166653 | COMPOSITIONS OF HIGH SPECIFIC ACTIVITY SN-117M AND METHODS OF PREPARING THE SAME - Compositions of high specific activity | 07-01-2010 |
| 20100196268 | Compositions and methods for treatment of tumors by direct administration of a radioisotope - This invention provides a safer and more effective treatment for non-intracavitary undesirable tissue masses, especially bone cancer and soft tissue tumors. The method involves the direct administration of a therapeutically-effective dose of a formulated radioisotope composition nearby or directly into the tissue mass. Small volumes of the composition are used. | 08-05-2010 |
| 20100215573 | IGF-1R SPECIFIC ANTIBODIES USEFUL IN THE DETECTION AND DIAGNOSIS OF CELLULAR PROLIFERATIVE DISORDERS - The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R. | 08-26-2010 |
| 20100233081 | METHODS FOR ADMINISTRATION OF RADIOTHERAPEUTIC AGENTS - A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent. Thus, not only does the combination effectively kill the transit amplifying cell population, the most rapidly replicating type of cell in a tumor, but it also effectively kills the tumor stem cells, which give rise to the transit amplifying cells, for a longer lasting anticancer effect. | 09-16-2010 |
| 20100260670 | ALTERNATIVE SPLICE VARIANT PATTERNS OF HUMAN TELOMERASE REVERSE TRANSCRIPTASE (hTERT) IN THYROID TUMORS TO DISTINGUISH BENIGN FROM MALIGNANT - This invention relates, e.g., to a method for determining if a thyroid tumor in a subject is malignant, comprising determining in a sample from the subject the amount of TERT (telomerase reverse transcriptase) mRNA which lacks the β sequence and the amount of TERT mRNA in the sample which comprises the β sequence, wherein a preponderance (e.g., at least about 55%) of TERT mRNA in the sample which comprises the β sequence indicates that the tumor is malignant, and wherein a preponderance of TERT mRNA which lacks the β sequence indicates that the tumor is not malignant. | 10-14-2010 |
| 20100278729 | BREAST CANCER ERADICATION PROGRAM - A method of treating breast cancer that is at least partially ER | 11-04-2010 |
| 20100284912 | HOMOGENIZATION OF A RADIOPHARMACEUTICAL USING SONIFICATION AND/OR ROTOR-STATOR TECHNOLOGY TO PRODUCE A HOMOGENOUS SUSPENSION, EMULSION, MIXTURE OR SOLID SUSPENSION OF IMMISCIBLE INGREDIENTS - A homogenous dispersion of aqueous droplets of a radiopharmaceutical or radiodiagnostic agent within a non-aqueous medium and method of making the same is provided. The homogenous dispersion is largely free of impurities and constitutes a substantially uniform distribution of sodium thiosulfate and radiopharmaceutical which is stable for a time sufficient to fill and solidify within gel capsules. In making the homogenous dispersion, dry sodium thiosulfate and dry potassium phosphate dibasic anhydrous are uniformly dispersed within non-aqueous, liquid polyethylene glycol. | 11-11-2010 |
| 20100316565 | NOVEL IMAGING METHOD - The present invention relates to a method useful in facilitating the identification of fibrogenesis in a subject. The method of the invention is particularly useful when applied as part of a method to diagnose fibrogenesis of the liver. The invention also provides a compound for use in a method for identification of fibrogenesis in a subject A further aspect of the invention is a compound for use in the preparation of a medicament for use in a method for identification of fibrogenesis in a subject. | 12-16-2010 |
| 20110038792 | INDUCTION OF THYROID IODIDE-HANDLING GENE EXPRESSION IN HUMAN CANCERS - Dual suppression of the MAP kinase and PI3K/Akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of G | 02-17-2011 |
| 20110044897 | METHOD OF IMAGING LOCALIZED INFECTIONS - The invention relates to a method for targeting an imaging agent to cells of an animal to detect localized infections. More particularly, localized infections are detected by targeting imaging agents to inflammatory cells having receptors for a vitamin by using vitamin-imaging agent conjugates. | 02-24-2011 |
| 20110064655 | BIOMARKERS FOR DEPRESSION - Differential expression of nucleic acids in the brains of subjects suffering from late-onset depression has been demonstrated. The invention provides methods useful in the determination of late-onset depression. Also provided by the present invention is a screening method for the identification of compounds for treatment, prevention or diagnosis of late-onset depression. | 03-17-2011 |
| 20110123445 | TREATMENT MONITORING - The present invention provides a method for monitoring the effectiveness of atreatment, wherein said treatment comprises an inhibitor designed to treat a disease comprising abnormal activity of the Ras/Raf/MEK/ERK pathway. | 05-26-2011 |
| 20110129417 | ADMINISTRABLE COMPOSITIONS - The present invention relates to a composition suitable for administration to a subject, the composition comprising pharmacologically acceptable particulate material dispersed throughout a pharmacologically acceptable liquid carrier, the particulate material being maintained in the dispersed state by a steric stabiliser, wherein the steric stabiliser is a polymeric material comprising a steric stabilising polymeric segment and an anchoring polymeric segment, one or both of which are derived from one or more ethylenically unsaturated monomers that have been polymerised by a living polymerisation technique, wherein the steric stabilising polymeric segment is different from the anchoring polymeric segment, and wherein the anchoring polymeric segment has an affinity toward the surface of the particulate material and secures the stabiliser to the particulate material. | 06-02-2011 |
| 20110150762 | BONE CEMENT CONTAINING BONE MARROW - A bone cement configured to be introduced to a target bone location and allowed to cure includes at least a monomer, and an amount of bone marrow. The resulting cured bone cement includes at least one desired mechanical property that can be tailored to match a like mechanical property of the target bone. The mechanical property can be a material stiffness (Young's modulus) or yield strength. | 06-23-2011 |
| 20110150763 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS - The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases. | 06-23-2011 |
| 20110229408 | SODIUM-IODIDE SYMPORTER GENE REPRESSOR BINDING SITE - The present disclosure relates to a sodium iodide symporter (NIS)-repressor binding sites (NRBS) consensus sequence consisting of a DNA molecule having the sequence 5′-T/C(G/A)GCCT(T/C)A(G/A)TTTCCCCA(T/C)CTGT-3′(the “consensus NRBS”). The disclosure further relates to methods of restoring iodide transport in dedifferentiated thyroid cancer cells by interfering with formation or function of the NIS repressor. | 09-22-2011 |
| 20110318265 | Coupled identification and treatment of cancer - Provided are methods to treat cancer in which a patient is identified as having gallium-avid cancer by use of a gallium scan or other means, and is then treated with a pharmaceutically acceptable gallium composition. | 12-29-2011 |
| 20120027675 | TARGETING PULMONARY EPITHELIUM USING ADRP - This invention provides novel compositions and methods for the specific and/or preferential delivery of an effector (e.g. a drug or label) to an epithelial cell (e.g. a pulmonary epithelium). The compositions comprise an adipocyte differentiation-related protein (ADRP) attached to an effector thereby forming a chimeric moiety. The chimeric moiety is preferentially delivered to epithelial cells. | 02-02-2012 |
| 20120064002 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1- ,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents - Enantiomer-pure compounds of general formulas VIIa and VIIb | 03-15-2012 |
| 20120134921 | SOLID COMPOSITIONS COMPRISING 5-AMINOLEVULINIC ACID - This invention relates to solid compositions and solid pharmaceutical products for use in methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions in the lower part of the gastrointestinal system. The solid pharmaceutical compositions and pharmaceutical products comprise an active ingredient which is 5-aminolevulinic acid (5-ALA) or a precursor or derivative of 5-ALA or pharmaceutically acceptable salts thereof. The invention relates further to methods of photodynamic diagnosis of cancer, pre-cancerous and non-cancerous conditions of the lower gastrointestinal tract, wherein the solid pharmaceutical compositions and pharmaceutical products are used. | 05-31-2012 |
| 20120164069 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 06-28-2012 |
| 20120213700 | COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN - The subject invention relates to the compositions for radiolabeling Diethylenetriaminepentaacetic Acid (DTPA)-dextran with Technetium-99m and for stabilizing the DTPA-dextran Cold Kit. The composition contains Stannous Chloride ions to reduce | 08-23-2012 |
| 20120251442 | Methods for Treatment of Tumors by Direct Administration of a Radioisotope - This invention provides a safer and more effective treatment for non-intracavitary undesirable tissue masses, especially bone cancer and soft tissue tumors. The method involves the direct administration of a therapeutically-effective dose of a formulated radioisotope composition nearby or directly into the tissue mass. Small volumes of the composition are used. | 10-04-2012 |
| 20120276003 | COMPOUND CONTAINING AN OXYGEN-15, PREPARATION AND USE THEREOF, AND COMPOSITION COMPRISING THEREOF - The present disclosure relates to a compound comprising an oxygen-15 and a process for preparation thereof. It also relates to the use of the compound in positron and/or other nuclide imaging and use of the compound in obtaining a perfusion and/or metabolic image in an animal and/or human body. A process for preparing the compound comprises irradiating a compound comprising oxygen via irradiation energy in the range of 10 MeV to 430 MeV. The oxygen atom in the compound may then be allowed to be converted to an oxygen-15 positron nuclide through a photonuclear reaction. Provided that the molecular structure of the irradiated compound is not disrupted, a compound comprising an oxygen-15 is prepared. | 11-01-2012 |
| 20120276004 | HUMAN MYELOID DERIVED SUPPRESSOR CELL CANCER MARKERS - Provided herein are methods for determining the presence of cancer (malignant versus benign), monitoring the progression of cancer, monitoring cancer relapse, monitoring the response to cancer therapy, or cancer staging in a subject, by evaluating CD33 | 11-01-2012 |
| 20120282179 | Methods of Using C-Met Modulators - Methods of treating cancer by administering a compound of Formula I, | 11-08-2012 |
| 20120315217 | INVERSE AGONISTS AND NEUTRAL ANTAGONISTS FOR THE TSH RECEPTOR - TSHR inverse agonists and neutral antagonists that are useful for treating Graves' orbitopathy, Graves' hyperthyroidism and/or thyroid cancer. | 12-13-2012 |
| 20130004418 | INFILTRATION SOLUTION FOR TREATING AN ENAMEL LESION - The invention relates to an infiltration solution of a radiopaque metal compound for treating an enamel lesion, to a kit for dental application, and to the use thereof for preventing and/or treating (sealing) carious enamel lesions. | 01-03-2013 |
| 20130022541 | FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death - Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to treat diseases involving CD74 | 01-24-2013 |
| 20130052131 | NANOPARTICLES, METHODS OF MAKING NANOPARTICLES, AND METHODS OF USE - Embodiments of the present disclosure, in one aspect, relate to a nanoparticle, methods of imaging a tumor, method of imaging a disease, method of treating a condition, disease, or related biological event, or the like. | 02-28-2013 |
| 20130095034 | Anti-CD74 Immunoconjugates and Methods - Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods. | 04-18-2013 |
| 20130136690 | ISOTOPE PREPARATION METHOD - The present invention provides a method for the generation of | 05-30-2013 |
| 20130224112 | COMPOSITIONS AND METHODS FOR SURFACE ABRASION WITH FROZEN PARTICLES - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 08-29-2013 |
| 20130230458 | Cell Permeable Inhibitors of Anaphase Promoting Complex - The invention provides compositions and methods for treating cell cycle disorders. Compositions of the invention include proTAME, a prodrug analog of TAME, and, optionally, one or more therapeutic agents. | 09-05-2013 |
| 20130251631 | LOW MOLECULAR WEIGHT THYROID STIMULATING HORMONE RECEPTOR (TSHR) AGONISTS - Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder. | 09-26-2013 |
| 20130302244 | METHOD OF PREPARING IODINE SEED FOR TREATING EYE DISEASE OR CANCER, AND IODINE SEED PREPARED THEREBY - The present invention provides a technique for adsorbing I-125 on a support for treating cancer and a method of preparing an I-125 seed using the same. Since a method of preparing iodine according to the present invention uses an intermediate having phosphate-based, oxalate-based, or arsenate-based anions introduced thereinto, the intermediate has a substitution effect of iodine 3 to 5 times higher than that of a typically used intermediate having chlorine anions introduced thereinto. According to the substitution effect, control of a radiation dose may be possible during the manufacturing of an iodine seed and an iodine seed may be prepared within a shorter period of time. Also, since an amount of residual radioactive iodine may be decreased as a result of a large amount of adsorption, an amount of radioactive iodine (I-125) waste may be decreased, and the effect thereof may be also high environmentally. | 11-14-2013 |
| 20130343988 | Pyrido [2, 3-D] pyrimidin-7-one compounds as inhibitors of P13K-Alpha for the treament of cancer - The invention is directed to Compounds of Formula (I). The invention provides compounds that inhibit, regulate, and/or modulate P13K that are useful in the treatment of hyperproliferative diseases, such as cancer. | 12-26-2013 |
| 20140079630 | CARBON NANOTUBES FOR IMAGING AND DRUG DELIVERY - The invention provides compositions and methods for visualizing particular tissues and delivering one or more therapeutics to that tissue using single-walled carbon nanotubes (SWNTs), which are taken up and delivered to target tissues by specific monocytes in the body. The delivery of SWNT to target tissues allows the visualization of the affected tissue for diagnostics and therapy in diseases where the specific monocyte is implicated in the disease pathogenesis. These nanotubes can be conjugated to a peptide, such as RGD, which helps direct the SWNT-containing monocytes to the vascular endothelium. | 03-20-2014 |
| 20140093451 | Coupled identification and treatment of cancer - Provided are methods to treat cancer, in which (1) a patient is first identified as having a cancer that is likely to be susceptible to gallium therapy, by the use of a gallium scan or other procedure that shows whether the cancer is gallium-avid, and (2) the patient is then treated with a pharmaceutically acceptable gallium composition. | 04-03-2014 |
| 20140099261 | DISTINGUISHING BENIGN AND MALIGNANT INDETERMINATE THYROID LESIONS - The application describes methods for accurately evaluating whether thyroid test samples, especially indeterminate thyroid samples, are benign or malignant. | 04-10-2014 |
| 20140134104 | CANCER THERAPY - The invention provides a method of treating a tumor or other lesion comprising introducing a solution comprising one or more radioactive isotopes directly into said tumour or other lesion in a mammal to effect in situ precipitation of a radioactive precipitate in the tumour or other lesion. | 05-15-2014 |
| 20140193335 | DEVICES AND METHODS FOR THE TREATMENT OF CANCER - The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer. | 07-10-2014 |
| 20140335017 | STRONTIUM PHOSPHATE MICROPARTICLE FOR RADIOLOGICAL IMAGING AND THERAPY - This invention relates to strontium-phosphate microparticles that incorporate radioisotopes for radiation therapy and imaging. | 11-13-2014 |
| 20140341803 | STABLE NANOEMULSIONS USEFUL IN THE TREATMENT OF CANCER - Described herein are methods for treating a tumor or cancer in a subject. The methods involve administering to the subject a nanoemulsion comprising (1) at least one perfluoro crown ether and (2) a block copolymer comprising a hydrophilic block and hydrophobic block, wherein the hydrophobic block is poly(d,l)lactic acid, and wherein the nanoemulsion comprises a therapeutic agent encapsulated in the nanoemulsion. The methods do not require the application of ultrasound or other sources of radiation in order to treat a tumor or cancer in the subject. | 11-20-2014 |
| 20140356282 | 100Mo compounds as accelerator targets for production of 99mTc - Methods of synthesizing | 12-04-2014 |
| 20150064108 | METHOD OF PREPARING RADIOISOTOPE HYBRID NANOCOMPOSITE PARTICLES USING SOL-GEL REACTION AND RADIOISOTOPE HYBRID NANOCOMPOSITE PARTICLES PREPARED USING THE SAME - A method of preparing radioisotope hybrid nanocomposite particles using a sol-gel reaction, and radioisotope hybrid nanocomposite particles prepared using the same are provided. The method includes preparing a complex precursor using a metal ion and an unshared electron pair reactive compound, growing hybrid nanocomposite particles based on the complex precursor by means of a sol-gel reaction, calcining the nanocomposite particles in the air to remove organic matters present in the nanocomposite particles, and irradiating the nanocomposite particles with neutrons to prepare radioisotope hybrid nanocomposite particles. The radioisotope nanocomposite particles prepared using the method can be used as diagnostic and therapeutic particles in the fields of oil refining, chemistry, cement, agriculture, water resources, environment, ocean, and medicine, and can also be used as a radioisotope tracer for evaluating the risk of nanomaterials. | 03-05-2015 |
| 20150104386 | ISOTOPE PREPARATION METHOD - The present invention provides a method for the generation of | 04-16-2015 |
| 20150118155 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND MONITORING HYPERTHYROIDISM IN A FELINE - The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods. | 04-30-2015 |
| 20150125387 | DISTINGUISHING BENIGN AND MALIGNANT INDETERMINATE THYROID LESIONS - The application describes methods for accurately evaluating whether thyroid test samples, especially indeterminate thyroid samples, are benign or malignant. | 05-07-2015 |
| 20150297763 | DEVICES AND METHODS FOR THERAPEUTIC HEAT TREATMENT - A microparticle includes a plurality of magnetic nanoparticles having a Curie temperature between 40° and 100° C. The microparticle further includes a biocompatible polymer and/or biocompatible ceramic and a plurality of radiopaque nanoparticles. | 10-22-2015 |
| 20150343099 | COMBINATION COMPRISING RADIUM-223 FOR THE TREATMENT OF CANCER - The present invention relates to combinations comprising compounds A and B, compound A being a 17α-hydroxylase/C | 12-03-2015 |
| 20150359808 | COMPOSITIONS AND METHODS FOR REDUCING HEPATOTOXICITY ASSOCIATED WITH DRUG ADMINISTRATION - The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. | 12-17-2015 |
| 20160032003 | Therapeutic Use of Anti-CD22 Antibodies for Inducing Trogocytosis - Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-B cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention. In other embodiments, optimal dosages of therapeutic antibody may be selected by monitoring the degree of trogocytosis induced by anti-B cell antibodies. Other characteristics of anti-B-cell antibodies that may be monitored include inducing phosphorylation of CD22, CD79a and CD79b; inducing translocation of CD22, CD79a and CD79b to lipid rafts; inducing caspase-dependent apoptosis; increasing pLyn, pERKs and pJNKs; decreasing constitutively-active p38; or inducing mitochondrial membrane depolarization, generation of reactive oxygen species, upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-xl, Mcl-1 and Bcl-2. | 02-04-2016 |
| 20160038413 | Antimicrobial Amorphous Compositions - The present invention comprises compositions and methods for providing antimicrobial compositions. The antimicrobial compositions comprise gel delivery vehicles comprising stabilized silver, wherein ionic silver is provided to a site for antimicrobial purposes. Methods of making and using such compositions are taught, including application of the silver-containing gel compositions to wounds, burns, abrasions, cuts, surgical incision, sites where skin or organ integrity has been breached, and other sites to supply an antimicrobial environment. | 02-11-2016 |
| 20160122406 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE - This invention relates to analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC | 05-05-2016 |
